| Literature DB >> 32703215 |
Beatrice Machini1,2, Dejan Zurovac3,4, Beatrice Amboko3, Lucas Malla3, Robert W Snow3,4, Hillary Kipruto5,6, Thomas N O Achia5,7.
Abstract
BACKGROUND: Health workers' knowledge deficiencies about artesunate-based severe malaria treatment recommendations have been reported. However, predictors of the treatment knowledge have not been examined. In this paper, predictors of artesunate-based treatment knowledge among inpatient health workers in two hospital sectors in Kenya are reported.Entities:
Keywords: Artesunate; Knowledge; Predictors; Severe malaria
Mesh:
Substances:
Year: 2020 PMID: 32703215 PMCID: PMC7379778 DOI: 10.1186/s12936-020-03341-2
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Categories of the knowledge outcomes and study definitions
| Knowledge outcomes | National recommendations | Knowledge categories | Category definitions |
|---|---|---|---|
| Treatment policy for severe malaria | Artesunate for the following 3 severe malaria populations Children and non-pregnant adults; Pregnant women in 1st trimester Pregnant women in 2nd & 3rd trimester | High | Artesunate response for all 3 severe malaria populations |
| Medium | Artesunate response for 2 severe malaria populations | ||
| Low | Artesunate response for one or none of the populations | ||
| Artesunate dose | 2 Weight categories 3 mg/kg for child < 20 kg, 2.4 mg/kg for patient > 20 kg | High | Correct response for 2 weight categories |
| Medium | Correct response for one weight category | ||
| Low | No correct response for any of the weight categories | ||
| Artesunate dosing interval | 3 dosing intervals 12 h between 1st and 2nd dose 12 h between 2nd and 3rd dose 24 h between 3rd and 4th dose | High | Correct response for all 3 dosing intervals |
| Medium | Correct response for 2 dosing intervals | ||
| Low | Correct response for one or none of the dosing intervals | ||
| Artesunate preparation | Solutions for 2 artesunate preparation steps Bicarbonate for reconstitution Saline or 5% dextrose for dilution | High | Correct response for 2 preparation steps |
| Medium | Correct response for one preparation step | ||
| Low | No correct response for any of the preparation steps | ||
| Preferred route of artesunate administration | Intravenous slow bolus | High | IV slow bolus response |
| Low | Any other response |
Characteristics of study health workers
| Health worker characteristics | Government hospitals | Faith based hospitals | ||
|---|---|---|---|---|
| N = 367 | N = 330 | |||
| n | % | n | % | |
| Gender | ||||
| Male | 140 | 38.1 | 161 | 48.8 |
| Female | 227 | 61.9 | 169 | 51.2 |
| Age (years)a | ||||
| 35–70 | 138 | 37.6 | 57 | 17.4 |
| 21–35 | 229 | 62.4 | 271 | 82.6 |
| Pre-service training | ||||
| Clinician | 175 | 47.7 | 156 | 47.3 |
| Nurse | 192 | 52.3 | 174 | 52.7 |
| Inpatient experience (years)b | ||||
| < 5 | 203 | 55.8 | 249 | 75.5 |
| > 5 | 161 | 44.2 | 81 | 24.5 |
| Ward allocation | ||||
| Paediatric | 185 | 50.4 | 168 | 50.9 |
| Medical | 182 | 49.6 | 162 | 49.1 |
| Malaria endemicity | ||||
| High | 102 | 27.8 | 88 | 26.7 |
| Low | 265 | 72.2 | 242 | 73.3 |
| Exposure to artesunate interventions | ||||
| Case management training | 87 | 23.7 | 66 | 20.0 |
| Malaria guideline | 118 | 32.2 | 131 | 39.7 |
| Supportive supervision | 39 | 10.6 | 29 | 8.8 |
| Artesunate administration poster | 224 | 61.0 | 157 | 47.6 |
| Artesunate in stock | 276 | 75.2 | 257 | 77.9 |
a Denominator excludes 2 health workers with missing information in faith-based hospitals
b Denominator excludes 3 health workers with missing information in government hospitals
Health workers’ knowledge about artesunate-based severe malaria treatment recommendations
| Health workers’ knowledge | Government hospitals | Faith based hospitals | ||
|---|---|---|---|---|
| N = 367 | N = 330 | |||
| n | % | n | % | |
| Treatment policy for severe malariaa | ||||
| High | 113 | 30.8 | 108 | 32.9 |
| Medium | 131 | 35.7 | 101 | 30.8 |
| Low | 123 | 33.5 | 119 | 36.3 |
| Artesunate doseb | ||||
| High | 186 | 50.8 | 220 | 66.7 |
| Medium | 100 | 27.3 | 67 | 20.3 |
| Low | 80 | 21.9 | 43 | 13.0 |
| Artesunate dosing intervals | ||||
| High | 123 | 33.5 | 110 | 33.3 |
| Medium | 136 | 37.1 | 137 | 41.5 |
| Low | 108 | 29.4 | 83 | 25.2 |
| Artesunate preparation | ||||
| High | 183 | 49.9 | 184 | 55.8 |
| Medium | 134 | 36.5 | 114 | 34.5 |
| Low | 50 | 13.6 | 32 | 9.7 |
| Preferred route of administration | ||||
| High | 289 | 78.7 | 272 | 82.4 |
| Low | 78 | 21.3 | 58 | 17.6 |
a Denominator excludes 2 health workers with missing information in faith-based hospitals
b Denominator excludes 1 health worker with missing information in government hospitals
Predictors of health workers knowledge about artesunate-based severe malaria treatment recommendations at government hospitals—multivariable models
| Health workers’ knowledge on | Treatment policy | Artesunate dose | Artesunate dosing interval | Artesunate preparation | Artesunate route of administration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aOR | 95% CI | P value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | |
| Age | |||||||||||||||
| 35–70 years | 1.0 (ref) | 1.0 (ref) | |||||||||||||
| 21–35 years | 1.70 | 0.96–3.01 | 0.071 | 1.19 | 0.71–2.02 | 0.509 | |||||||||
| Gender | |||||||||||||||
| Female | 1.0 (ref) | ||||||||||||||
| Male | 1.17 | 0.74–1.85 | 0.497 | ||||||||||||
| Cadre | |||||||||||||||
| Nurse | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | |||||||||||
| Clinician | 1.86 | 1.18–2.91 | 0.007 | 1.14 | 0.66–1.95 | 0.645 | 1.23 | 0.75–2.05 | 0.412 | 0.80 | 0.53–1.20 | 0.272 | |||
| Ward | |||||||||||||||
| Medical | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | |||||||||||
| Paediatric | 1.99 | 1.30–3.04 | 0.002 | 1.49 | 1.00–2.23 | 0.052 | 1.99 | 1.33–2.99 | 0.001 | 1.56 | 0.89–2.76 | 0.123 | |||
| Endemicity | |||||||||||||||
| Low | 1.0 (ref) | ||||||||||||||
| High | 2.97 | 1.04–8.46 | 0.042 | ||||||||||||
| CM guidelines | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
| Yes | 1.49 | 0.91–2.42 | 0.110 | 1.54 | 0.97–2.45 | 0.069 | 1.29 | 0.66–2.52 | 0.461 | ||||||
| CM training | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
| Yes | 2.31 | 1.44–3.72 | 0.001 | 1.58 | 0.96–2.60 | 0.071 | 1.95 | 0.86–4.39 | 0.108 | ||||||
| Supervision | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | |||||||||||||
| Yes | 1.65 | 0.84–3.22 | 0.065 | 2.09 | 0.96–4.55 | 0.062 | |||||||||
| AS poster | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||
| Yes | 1.21 | 0.78–1.90 | 0.398 | 2.17 | 1.24–3.79 | 0.007 | 1.43 | 0.85–2.42 | 0.179 | 1.40 | 0.88–2.22 | 0.154 | 2.19 | 1.05–4.57 | 0.037 |
| AS in stock | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
| Yes | 1.38 | 0.72–2.65 | 0.335 | 1.52 | 0.82–2.82 | 0.183 | 1.35 | 0.79–2.30 | 0.278 | ||||||
| Survey | |||||||||||||||
| Baseline | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||
| Follow up | 1.83 | 1.22–2.74 | 0.004 | 2.01 | 1.28–3.16 | 0.002 | 1.55 | 1.02–2.37 | 0.042 | 1.30 | 0.85–1.98 | 0.221 | 1.20 | 0.66–2.20 | 0.549 |
CM case-management, AS artesunate
Predictors of health workers knowledge about artesunate-based severe malaria treatment recommendations at faith based hospitals—multivariable models
| Health workers’ knowledge on | Treatment policy | Artesunate dose | Artesunate dosing interval | Artesunate preparation | Artesunate route of administration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | |
| Age (years) | |||||||||||||||
| 35–70 | 1.0 (ref) | ||||||||||||||
| 21–35 | 0.70 | 0.36–1.31 | 0.260 | ||||||||||||
| Gender | |||||||||||||||
| Female | 1.0 (ref) | 1.0 (ref) | |||||||||||||
| Male | 1.02 | 0.63–1.65 | 0.941 | 0.67 | 0.42–1.06 | 0.090 | |||||||||
| Cadre | |||||||||||||||
| Nurse | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
| Clinician | 2.27 | 1.41–3.65 | 0.001 | 2.24 | 1.33–3.77 | 0.002 | 1.76 | 1.15–2.69 | 0.009 | ||||||
| Endemicity | |||||||||||||||
| Low | 1.0 (ref) | ||||||||||||||
| High | 5.79 | 1.17–28.67 | 0.031 | ||||||||||||
| CM guidelines | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | |||||||||||||
| Yes | 2.41 | 1.48–3.93 | <0.001 | 1.59 | 0.99–2.55 | 0.054 | |||||||||
| CM training | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
| Yes | 1.33 | 0.74–2.39 | 0.335 | 1.24 | 0.71–2.16 | 0.457 | 1.82 | 0.99–3.35 | 0.056 | ||||||
| Supervision | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | |||||||||||||
| Yes | 3.37 | 0.94–12.0) | 0.061 | 1.42 | 0.64–3.16 | 0.391 | |||||||||
| AS poster | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
| Yes | 1.07 | 0.59–1.95 | 0.829 | 2.02 | 0.93–4.37 | 0.074 | 1.49 | 0.86–2.60 | 0.154 | 1.67 | 0.93–2.99 | 0.087 | |||
| AS in stock | |||||||||||||||
| No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | |||||||||||
| Yes | 2.01 | 1.05–3.85 | 0.036 | 2.18 | 1.20–3.94 | 0.010 | 1.61 | 0.88–2.96 | 0.121 | 4.73 | 1.50–14.89 | 0.008 | |||
| Survey | |||||||||||||||
| Baseline | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | |||||||||||
| Follow up | 1.61 | 0.94–2.77 | 0.085 | 1.31 | 0.70–2.45 | 0.392 | 1.09 | 0.66–1.82 | 0.733 | 1.38 | 0.81–2.36 | 0.240 | |||
CM case management, AS artesunate